glp-1 news nov 2025 ISPOR 2025: Exploring reasons for discontinuation Boston, USA. 16th Nov, 2025.

Patients with syndromic obesity also exhibit congenital malformations and intellectual disabilities

What people complain about: Slow titration is a major complaint

Wegovy and Saxenda coverage depends on whether your plan includes weight management benefits

Unlike traditional GLP-1 receptor agonists, tirzepatide is more selective for the GIP receptor, resulting in a more balanced activation of these receptors

doi: 10.1210/endo.140.11.7143 15 MeierJJNauckMAKranzDHolstJJDeaconCFGaecklerDet al

Sometimes the medication may not work for you, or you may not be able to tolerate the full dose due to side effects in which case your practitioner will provide additional options or change the protocol to better suit your individual needs